The syrup launched by company's Chezgreen division is designed to provide supportive care in managing common menstrual concerns such as amenorrhea, dysmenorrhea, and menorrhagia
The newly licensed platform enables precise control over both the drug-to-antibody ratio and payload attachment sites in single- and dual-payload ADCs
Hikal’s Q4 profit remained sharply lower year-on-year, falling 71% from Rs. 50.2 crore in Q4 FY25 as the company absorbed regulatory pressures and strategic accounting adjustments
On a full-year basis, revenue from operations for FY26 grew 18.9 percent year-on-year to Rs 827.87 crore compared to Rs 696.48 crore in FY25
Under the new initiative, each company takes on a defined role across the recycling chain
PAT soars 201%, EBITDA up 88% on strong PHPO demand & margin expansion
Madhav Bhutada says overdependence on large CDMOs and delayed engagement can increase development costs by up to 40% and slow clinical progress
Company launches clinical study of AI-designed oral formulation following MHRA approval, marking a major milestone in AI-driven drug development.
The finance leader and investment banking veteran to steer global financial strategy, investor relations, and growth initiatives
POSEIDON is among the largest global datasets to quantify this residual inflammatory burden
Subscribe To Our Newsletter & Stay Updated
